| Parameter |
|
|
| Gender, n (%) | Male | 22 (73) |
|
| Female | 8 (27) |
| Age (years) | Median (range) | 67 (32 - 85) |
| Primary tumor site, n (%) | Right-sided | 7 (23) |
|
| Left-sided | 23 (77) |
| KRAS wild type, n (%) | Yes | 30 (100) |
|
| No | 0 (0) |
| Other RAS genotype, n (%) | Wild-type | 23 (77) |
|
| Mutant-type | 7 (23) |
| ECOG PS at baseline, n (%) | 0 - 1 | 26 (87) |
|
| 2 - 3 | 4 (13) |
| Organs with metastases, n (%) | 0 - 2 | 25 (83) |
|
| 3 | 5 (17) |
| Lymph node metastasis at baseline, n (%) | Positive | 15 (50) |
|
| Negative | 15 (50) |
| Peritoneal metastasis at baseline, n (%) | Positive | 6 (20) |
|
| Negative | 24 (80) |
| Histological grade, n (%) | 1 - 2 | 25 (83) |
|
| 3 - 4 | 5 (17) |
| CEA at baseline, n (%) | <5.0 ng/ml | 13 (43) |
|
| ≥5.0 ng/ml | 17 (57) |
| Treatment regimen, n (%) | FOLFOX | 20 (67) |
|
| SOX | 4 (13) |
|
| FOLFILI | 6 (20) |
| Oxaliplatin-based adjuvant chemotherapy, n (%) | Yes | 7 (23) |
|
| No | 23 (77) |